Welcome to our dedicated page for Alterity Therapeutics SEC filings (Ticker: ATHE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The SEC filings page for Alterity Therapeutics Limited (ATHE) provides access to the company’s disclosures as a foreign private issuer listed on NASDAQ. Alterity files reports under the Securities Exchange Act of 1934, including its annual report on Form 20‑F and current reports on Form 6‑K, and describes itself in these documents as a development stage enterprise focused on neurodegenerative diseases.
For investors following this clinical stage biotechnology company, Form 6‑K filings are particularly important. They often include material that has been released to the Australian Securities Exchange, such as quarterly Appendix 4C cash flow reports, clinical trial updates for ATH434 in Multiple System Atrophy (MSA), regulatory designations like U.S. FDA Fast Track status, and information on capital raisings or strategic placements. Other 6‑K submissions may contain meeting results, presentations to shareholders, and notices related to board or director changes.
Alterity’s Form 20‑F annual report (when filed) typically consolidates information on its business overview, risk factors, research and development focus on Parkinsonian and other neurodegenerative disorders, and its status as a clinical stage company. These filings complement the company’s scientific and clinical communications by outlining its segment focus on research and development and its listing arrangements on the Australian Securities Exchange and NASDAQ.
On Stock Titan, this page surfaces Alterity’s SEC filings as they are made available from EDGAR and pairs them with AI‑powered summaries to help readers interpret technical language. Users can quickly see the purpose of each 6‑K or 20‑F, identify items related to ATH434 clinical data, regulatory interactions, cash flow disclosures, and corporate governance, and then drill into the full text for detailed review.
Alterity Therapeutics has submitted a Form 6-K to announce an upcoming corporate update regarding ATH434, their key therapeutic candidate. The filing indicates that CEO Geoffrey P. Kempler will provide details about the company's progress through Exhibit 99.1.
Key points from this filing include:
- Filed as a foreign private issuer under Rule 13a-16/15d-16
- Company files annual reports under Form 20-F
- Filing will be incorporated into multiple registration statements including Form S-8 (Files No. 333-251073, 333-248980, 333-228671) and Form F-3 (Files No. 333-274816, 333-251647, 333-231417, 333-250076)
- Document signed by Geoffrey P. Kempler in his capacity as Chairman
This filing suggests potential material developments regarding ATH434, which could be significant for investors following Alterity's drug development pipeline. The corporate update may include clinical progress, regulatory developments, or other strategic initiatives related to their therapeutic program.